Page 10 - Vaccines Task News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BARROW has been highlighted as a location targeted for 30,000 new jobs in UK steel fabrication to build approximately 300 giant wind turbines each year. This comes following demand in order to meet the net zero carbon by 2050 target and is vital for levelling up coastal and industrial areas says GMB. As things stand, without a Renewables Development Authority to develop UK capacity, these steel fabrication jobs are destined to be in Asia with the only role for UK workers being to pay for them which is unnecessary and politically unacceptable says GMB Scotland. Up to 30,000 new jobs ar...

DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 15.04.2021 / 13:30 CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine e...

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 - COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021 - Phase 2a trial in Peru and Panama amended for addition of secondary endpoint for vaccine efficacy in total population with a focus on participants over the age...

Date Time Alternating vaccines trial expands to include two additional vaccines Experts from the University of Nottingham are looking for people who have had their first Covid-19 vaccination in the past 8-12 weeks, to take part in an extended study investigating alternating doses of two new approved vaccines. Researchers who were part of the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AztraZeneca vaccine and the Pfizer vaccine, have today announced an extension to this programme, to include the Moderna and Novavax vaccines in a new study. The trial is le...

I urge Premier Moe to heed the advice of physicians in the decisions needed to bring the pandemic under control, writes George Peters.